Skip to main navigation Skip to search Skip to main content

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50

  • Robert W. Haile
  • , Duncan C. Thomas
  • , Valerie McGuire
  • , Anna Felberg
  • , Esther M. John
  • , Roger L. Milne
  • , John L. Hopper
  • , Mark A. Jenkins
  • , A. Joan Levine
  • , Mary M. Daly
  • , Saundra S. Buys
  • , Ruby T. Senie
  • , Irene L. Andrulis
  • , Julia A. Knight
  • , Andrew K. Godwin
  • , Melissa Southey
  • , Margaret R.E. McCredie
  • , Graham G. Giles
  • , Lesley Andrews
  • , Katherine Tucker
  • Alexander Miron, Carmel Apicella, Andrea Tesoriero, Anita Bane, Malcolm C. Pike, Alice S. Whittemore
  • University of Southern California
  • Stanford University
  • Cancer Prevention Institute of California
  • University of Melbourne
  • University of Utah
  • Columbia University
  • Fred A. Litwin Center for Cancer Genetics
  • University of Toronto
  • Fox Chase Cancer Center
  • Early Detection Laboratory
  • University of Otago
  • Cancer Council Victoria
  • Prince of Wales Hospital
  • Dana-Farber Cancer Institute

Research output: Contribution to journal › Article › peer-review

108 Scopus citations

Abstract

Background: Understanding the effect of oral contraceptives on risk of breast cancer in BRCA1 or BRCA2 mutation carriers is important because oral contraceptive use is a common, modifiable practice. Methods: We studied 497 BRCA1 and 307 BRCA2 mutation carriers, of whom 195 and 128, respectively, had been diagnosed with breast cancer. Case-control analyses were conducted using unconditional logistic regression with adjustments for family history and familial relationships and were restricted to subjects with a reference age under 50 years. Results: For BRCA1 mutation carriers, there was no significant association between risk of breast cancer and use of oral contraceptives for at least 1 year [odds ratio (OR), 0.77; 95% confidence interval (95% CI), 0.53-1.12] or duration of oral contraceptive use (Ptrend = 0.62). For BRCA2 mutation carriers, there was no association with use of oral contraceptives for at least 1 year (OR, 1.62; 95% CI, 0.90-2.92); however, there was an association of elevated risk with oral contraceptive use for at least 5 years (OR, 2.06; 95% CI, 1.08-3.94) and with duration of use (ORtrend per year of use, 1.08; P = 0.008). Similar results were obtained when we considered only use of oral contraceptives that first started in 1975 or later. Conclusions: We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50. For BRCA2 mutation carriers, use of oral contraceptives may be associated with an increased risk of breast cancer among women who use them for at least 5 years. Further studies reporting results separately for BRCA1 and BRCA2 mutation carriers are needed to resolve this important issue.

Original languageEnglish
Pages (from-to)1863-1870
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number10
DOIs
StatePublished - Oct 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Australia/epidemiology
  • Breast Neoplasms/epidemiology
  • Canada/epidemiology
  • Carcinoma in Situ/epidemiology
  • Carcinoma, Ductal, Breast/epidemiology
  • Case-Control Studies
  • Contraceptives, Oral/pharmacology
  • Female
  • Genes, BRCA1/drug effects
  • Genes, BRCA2/drug effects
  • Genetic Predisposition to Disease
  • Heterozygote
  • Humans
  • Logistic Models
  • Middle Aged
  • Mutation/drug effects
  • Receptors, Estrogen/drug effects
  • Receptors, Progesterone/drug effects
  • Risk Factors
  • Surveys and Questionnaires
  • Time Factors
  • United States/epidemiology

Fingerprint

Dive into the research topics of 'BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50'. Together they form a unique fingerprint.

Cite this